You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc. (D. Del. 2014)

✉ Email this page to a colleague

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc. (D. Del. 2014)

Docket	⤷ Sign Up	Date Filed	2014-08-13
Court	District Court, D. Delaware	Date Terminated	2019-03-27
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	NOVARTIS PHARMACEUTICALS CORPORATION
Patents	6,004,973; 6,239,124; 6,440,990; 6,455,518; 8,410,131; 8,778,962
Attorneys	Nicholas N. Kallas
Firms	Richards, Layton & Finger, PA; Selena E. Molina
Link to Docket	External link to docket

Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc. (D. Del. 2014)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2016-09-26	162	POST Trial Brief	of U.S. Patent No. 5,665,772 for Obviousness and the Invalidity of U.S. Patent Nos. 6,239,124 and 6,455,518…for Obviousness and for Obviousness-Type Double Patenting, by Breckenridge Pharmaceutical Inc.. (Farnan,…2014 27 March 2019 1:14-cv-01043 830 Patent None District Court, D. Delaware	External link to document
2016-10-17	169	POST Trial Brief	Brief Regarding Noninfringement of U.S. Patent Nos. 6,239,124 and 6,455,518, by Breckenridge Pharmaceutical…2014 27 March 2019 1:14-cv-01043 830 Patent None District Court, D. Delaware	External link to document
2016-10-25	174	POST Trial Brief	Obviousness of U.S. Patent No. 5,665,772, and Invalidity of U.S. Patent Nos. 6,239,124 and 6,455,518, by…2014 27 March 2019 1:14-cv-01043 830 Patent None District Court, D. Delaware	External link to document
2017-03-28	182	Opinion	induced infringement of U.S. Patent No. 6,239,124 ("the '124 patent") and Roxane and Par … later patent that are not patentably distinct from claims in a commonly owned earlier patent."&…772 PATENT A. Findings of Fact 1. The '990 patent is a proper double-patenting reference… the '990 patent is a proper double-patenting reference to the '772 patent, then the claims…post-DRAA patent to serve as a double patenting reference for a later expiring pre-DRAA patent would effectively	External link to document
2017-04-03	184	Opinion	induced infringement of U.S. Patent No. 6,239,124 ("the '124 patent") and Breckenridge, Roxane… later patent that are not patentably distinct from claims in a commonly owned earlier patent."&…772 PATENT A. Findings of Fact 1. The '990 patent is a proper double-patenting reference… the '990 patent is a proper double-patenting reference to the '772 patent, then the claims…post-URAA patent to serve as a double patenting reference for a later expiring pre-URAA patent would effectively	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.